Prevalence, co-infection and antibiotic resistance of *Escherichia Coli* from blood and urine samples at a hospital in Jamaica

Donna A Cheung¹, Alison Nicholson¹, Tiffany R Butterfield¹, Marsha DaCosta¹

¹ Department of Microbiology, The University of the West Indies, Mona, Jamaica

Abstract

Introduction: *Escherichia coli* (*E. coli*) is a very common uro-pathogen and pathogen of bloodstream infections (BSI) in Jamaica. The aim of this study was to examine this organism’s prevalence, determine co-infection rates and assess antibiotic resistance patterns.

Methodology: In the absence of automated systems, data on all *E. coli* isolates identified at the University Hospital of the West Indies in Kingston, Jamaica during the first six months of 2008 and 2012 was collected and sorted. Data were analyzed using IBM SPSS Statistics version 20 for Windows.

Results: A total of 1188 isolates (1072 from urine and 116 from blood) was analyzed. Patients with *E. coli* BSI were older than those with *E. coli* urinary tract infections (UTI) (55.3 years vs 42.4 years, p < 0.05) and both had a female predominance. Sensitivity profiles in 2012 for *E. coli* in blood and urine were highest for the carbapenems, Amikacin and Nitrofurantoin and lowest for the fluoroquinolones and Trimethoprim-sulfamethoxazole. Based on antimicrobial susceptibility patterns, Nitrofurantoin was identified as an appropriate choice for empiric therapy for UTI. Ten antibiotics were noted in this study to have developed statistically significant antibiotic resistance. Patients with *E. coli* BSI had a co-infection *E. coli* UTI rate of 39%.

Conclusions: Resistance patterns change drastically in a few years making frequent antimicrobial susceptibility profiling necessary. Further studies would be beneficial in guiding management of these patients.

Key words: *Escherichia coli*; urine; blood.

Systematic review: *Escherichia coli* (*E. coli*) has been recognized as a common pathogen implicated in urinary tract infections (UTI) and bloodstream infections (BSI). Internationally, *E. coli* has been shown to be the most common pathogen causing UTI in various populations in countries in North America, Latin America, Europe, and Asia [1-3]. In Jamaica, previous studies have also found *E. coli* to be the most common pathogen in urinary tract infections [4-5]. The contribution of *E. coli* in BSI is not as distinct as its role in UTI but *E. coli* has been found as a top pathogen in BSI. It is the most common gram negative bacilli causing BSI in North America and Latin America [6-7]. A previous study found *E. coli* to be the second most common gram negative bacteria in neonatal sepsis in Jamaica [8]. Over a decade ago, *E. coli* placed 5th alongside *Salmonella sp.* among the top pathogens causing bacteremia in Jamaica [9].

Because of the paramount role of *E. coli* in causing extra-intestinal infection, we carried out this study to determine the prevalence of (i) *E. coli* UTI, (ii) *E. coli* BSI, and (iii) *E. coli* blood and urine co-infection and to assess their respective trends and antibiotic resistance patterns over time.

Methodology

This was a cross-sectional study that compared data collected at the Department of Microbiology, University Hospital of the West Indies, Kingston, Jamaica from 2008 and 2012. Approval was granted by the UHWI/UWI/FMS Ethics Committee. Data was collected for the first 6 months of the respective years. *E. coli* isolates were identified by manual sorting of all blood and urine culture carbon copies of results issued by the department for those time periods. Demographic data, as well as the antibiotic susceptibility profile, were collected from these carbon copies. The intradepartmental log was also reviewed to ensure no isolates were missed.

The total number of *E. coli* isolated from blood and urine specimens from January 1, 2008, to December 31, 2012, was 6372 isolates. During the data collection period, urine specimens were noted to be missing for...
January and part of February 2008. Despite this, our study period had 1274 E. coli isolates which approximately represented 20% of all E. coli isolated for the 5-years period of which 86 were identified as duplicates as illustrated in Figure 1. Duplicates were defined as, E. coli isolated from the same patient and specimen type within the respective 6-months period with identical antibiotic susceptibility profiles. In total there were 1188 samples included in the study. There were no other exclusion criteria.

Co-infection was defined as having a positive blood and urine culture in the same patient. Accident and emergency, casualty and clinics were considered acute care settings.

Data were analyzed using IBM SPSS Statistics version 20 for Windows. A p value of < 0.05 was deemed to represent statistical significance.

**Results**

After removing duplicates from the 1274 E. coli isolates, there were 1188 isolates remaining. Of 1188 E. coli isolates in this study, 90% (1072) were from urine specimens and the remaining 10% (116) were from blood specimens. Isolates were evenly distributed between the years. Of E. coli urine specimens 57% were identified in 2012 and the remaining 43% were identified in 2008. Of E. coli blood specimens 55% were identified in 2008 and the remaining 45% were identified in 2012.

**Prevalence of E. coli UTI and BSI**

Patients with E. coli UTI were predominantly female (75.6%, n = 790). Obstetric patients accounted for 13% of E. coli UTI. The average age of a patient with E. coli UTI in 2008 was 42 years (range 21 days - 98 years) whereas in 2012 it was 43 years (range 2 days - 97 years). Children (< 12 years) accounted for 11% of isolates (2008 n = 49, 2012 n = 62). As seen in Figure 2, over two-thirds of E. coli isolated in urine was from specimens sent from an acute care setting.

Gender was more evenly distributed among patients with E. coli BSI (female 56.5%, n = 65). The average age of a patient with E. coli BSI was 50 years in 2008 compared to 60 years in 2012 (2008 range: 3 months-95 years, 2012 range: 4 months-93 years of age). An independent-samples t-test showed a significant difference in the average ages of patients with E. coli UTI (M = 42.40, SD = 25.69) and E. coli BSI (M = 55.34, SD = 24.52); t(1014) = -4.80, p < 0.05. Patients with E. coli BSI were older than patients with E. coli UTI.

E. coli isolated in blood was predominantly sent from specimens from an acute care setting as depicted in Figure 2.

**Prevalence of E. coli blood and urine co-infection**

Of the patients with E. coli BSI in 2008, 36% had a concurrent E. coli UTI whereas, in 2012, 42% of E. coli BSI had a concurrent E. coli UTI. Combined, 39% of patients with E. coli BSI had a concurrent E. coli UTI (n = 45). Conversely, of the 1072 urine samples with E. coli isolated only 4% had a concurrent E. coli BSI.

Females made up 70.3% of patients with co-infections. The average age was 62 with a range of 19-95 years of age. There were no children identified with co-infections. The majority of samples for co-infections were sent from the accident and emergency department. All co-infections identified in the clinic setting were from the Sickle Cell Unit (11%). No co-infections were identified from the critical care units. See Figure 2.

80% of these samples were received either on the same day or a day apart. 60% shared the same antibiotic susceptibility while 29% had a difference in susceptibility to one antibiotic. Of those that did not share the exact same susceptibility, 61% of them were from samples sent a day or more apart.
Antimicrobial Resistance

Antibiotic susceptibilities were similar for *E. coli* isolates causing UTI and *E. coli* isolates causing BSI. Overall, resistance was noted for ampicillin, trimethoprim-sulfamethoxazole, nalidixic acid, and the fluoroquinolones. Statistically significant resistance developed for *E. coli* isolates causing UTI to piperacillin-tazobactam, ceftazidime, cefuroxime, and tobramycin (> 10% decrease in susceptibility). Resistance also developed to nitrofurantoin and amikacin but the level of susceptibilities continued to remain high (89.6% and 95.1% respectively).

On the other hand, isolates became more susceptible to amoxicillin-clavulanate, cefazolin, and cefepime became more susceptible with time (22%, 34% and 56% increase respectively, p-value < 0.05). This increase in susceptibility to cefepime was noted for *E. coli* isolates causing UTI.

Obstetric patients are a unique population group as antibiotic choices are limited because of fetotoxic effects. Children as well have limitations to antibiotic options. The antibiotic susceptibility profiles for these subgroups groups were further analyzed and, in general, their resistance patterns correlated with that of the general population. See Table 1.

**Figure 2.** The specimen location of *E. Coli* UTI in (A) 2008 and (B) 2012, BSI in (C) 2008 and (D) 2012 and co-infection in (E) 2008 and 2012 at the University Hospital of the West Indies, Jamaica.
Table 1. Sensitivity profile of E. coli isolated from blood and urine samples collected from January to June of the years 2008 and 2012 at the University Hospital of the West Indies Jamaica.

| Antimicrobial | Overall Sensitivity | Children Sensitivity | Critical Care Unit Sensitivity | Obstetric Patients Sensitivity | p-value |
|---------------|---------------------|----------------------|-------------------------------|-------------------------------|---------|
|               | 2008                | 2012                 | 2008                         | 2012                         |         |
|               | p-value             | p-value              | p-value                      | p-value                      |         |
| Ak (Amikacin) |                     |                      |                              |                              |         |
| Blood         | 100%                | 97.90%               | > 0.05                       | 100%                         | 100%    |
| Urine         | 99.40%              | 95.10%               | < 0.05                       | 100%                         | 100%    |
| AMC (Amoxicillin-clavulanate) |     |                      |                              |                              |         |
| Blood         | 57.10%              | 84.20%               | < 0.05                       | 50%                          | 100%    |
| Urine         | 65%                 | 81.50%               | < 0.05                       | 61%                          | 70%     |
| AMP (Ampicillin) |                 |                      |                              |                              |         |
| Blood         | 35.90%              | 42.90%               | > 0.05                       | 40%                          | 0%      |
| Urine         | 43.50%              | 42.10%               | > 0.05                       | 31%                          | 34%     |
| AZT (Aztreonam) |                 |                      |                              |                              |         |
| Blood         |                     |                      |                              |                              |         |
| Urine         |                     |                      |                              |                              |         |
| CAZ (Ceftazidime) |             |                      |                              |                              |         |
| Blood         | 100%                | 91.90%               | > 0.05                       | 100%                         | 100%    |
| Urine         | 89%                 | 65.50%               | < 0.05                       | 95%                          | 86%     |
| CEFA (Cefazolin) |             |                      |                              |                              |         |
| Blood         | 54.20%              | 90%                  | < 0.05                       | 100%                         | 100%    |
| Urine         | 47%                 | 78.60%               | < 0.05                       | 36%                          | 90%     |
| CEFE (Cefepime) |             |                      |                              |                              |         |
| Blood         | 72%                 | 94.70%               | > 0.05                       | 100%                         | 100%    |
| Urine         | 33.30%              | 89.30%               | < 0.05                       | 94%                          | 94%     |
| CEFO (Cefoxitin) |             |                      |                              |                              |         |
| Blood         |                     |                      |                              |                              |         |
| Urine         |                     |                      |                              |                              |         |
| CIP (Ciprofloxacin) |           |                      |                              |                              |         |
| Blood         | 71.90%              | 65.10%               | > 0.05                       | 100%                         | 50%     |
| Urine         | 68.70%              | 63.10%               | > 0.05                       | 92%                          | 76%     |
| CN (Gentamicin) |             |                      |                              |                              |         |
| Blood         | 85.90%              | 76.50%               | > 0.05                       | 80%                          | 50%     |
| Urine         | 84.80%              | 81%                  | > 0.05                       | 91%                          | 81%     |
| CRO (Ceftriaxone) |             |                      |                              |                              |         |
| Blood         | 84.50%              | 87%                  | > 0.05                       | 100%                         | 100%    |
| Urine         | 85.80%              | 79.70%               | < 0.05                       | 87%                          | 93%     |
| CXM (Cefuroxime) |             |                      |                              |                              |         |
| Blood         | 75.80%              | 65.50%               | > 0.05                       | 80%                          | 0%      |
| Urine         | 78.50%              | 59.60%               | < 0.05                       | 88%                          | 83%     |
| ERT(Ertapenem) |             |                      |                              |                              |         |
| Blood         |                     |                      |                              |                              |         |
| Urine         |                     |                      |                              |                              |         |
| F (Nitrofurantoin) |            |                      |                              |                              |         |
| Blood         | 100%                | 90.50%               | > 0.05                       | 100%                         | 100%    |
| Urine         | 96.30%              | 89.60%               | < 0.05                       | 98%                          | 92%     |
| IMI (Imipenem) |             |                      |                              |                              |         |
| Blood         | 100%                | 100%                 |                              |                              |         |
| Urine         | 100%                | 99.40%               | > 0.05                       | 97%                          | 100%    |
| LEV (Levofloxacin) |             |                      |                              |                              |         |
| Blood         | 68%                 | 76.20%               | > 0.05                       | 100%                         | 0%      |
| Urine         | 65.70%              | 64%                  | > 0.05                       | 91%                          | 78%     |
| LZD (Linezolid) |             |                      |                              |                              |         |
| Blood         |                     |                      |                              |                              |         |
| Urine         |                     |                      |                              |                              |         |
Values reported represent the proportion of isolates sensitive to the various antibiotics.

E. coli isolates causing co-infections were similarly resistant to the fluoroquinolones, the aminoglycosides (with an exception), the tetracyclines, and ampicillin. They were however highly susceptible to the carbapenems, amikacin, and piperacillin-tazobactam. See Table 2.

**Discussion**

One of the main objectives of this study was to assess the prevalence of E. coli UTI and E. coli BSI. This study showed that a patient with E. coli UTI was more likely female in her 40s whereas a patient with E. coli BSI was much more likely to be significantly older. The female predominance found in this study matched that of findings found in other studies [10-12]. The mean age of patients with E. coli BSI in 2012 was 60 years which was in keeping with means found in other studies [11-13]. However, it is noticeable that far more patients that year were in the 13-30 age group. The reason behind this is beyond the scope of this study. Further studies could assess if improvements in health care practice, particularly among Jamaica’s at risk large sickle cell population, may have accounted for this change.

This study found an overall E. coli blood and urine co-infection rate of 39%. Three other studies were identified in the literature review that isolated E. coli in urine cultures among patients with E. coli BSI [11,12,14]. Co-infection rates of 45-63.5% were found in these studies [11,12,14]. This study found a lower co-infection rate which may be because of differences in the time period of study, population age and location. Despite the lower co-infection rate in our study, over a third of patients with E. coli BSI will have a concurrent E. coli UTI. Whether these cases represented E. coli UTI that progressed to E. coli bacteremia could not be determined with the data collected from this study. The patient at risk of co-infection was likely to be an elderly

| OVERALL SENSITIVITIES | CHILDREN | CRITICAL CARE UNIT | OBSTETRIC PATIENTS |
|------------------------|----------|---------------------|---------------------|
| **MEM** (Meropenem)    |          |                     |                     |
| Blood 2008             | 100%     | 100%                | 100%                |
| Blood 2012             | 100%     | 100%                |                      |
| p-value                |          |                     |                     |
|                       |          |                     |                     |
| **MHO** (Minocycline)  |          |                     |                     |
| Blood 2008             | 98.90%   | 95%                 | 100%                |
| Blood 2012             |          |                     |                     |
| p-value                | > 0.05   | > 0.05              |                     |
|                       |          |                     |                     |
| **NA** (Nalidixic Acid)|          |                     |                     |
| Blood 2008             | 61.40%   | 73%                 | 66.70%              |
| Blood 2012             |          |                     |                     |
| p-value                | > 0.05   | > 0.05              |                     |
|                       |          |                     |                     |
| **NOR** (Norfloxacin)  |          |                     |                     |
| Blood 2008             | 68.70%   | 88%                 | 87.50%              |
| Blood 2012             |          |                     |                     |
| p-value                | > 0.05   | > 0.05              |                     |
|                       |          |                     |                     |
| **POLY B** (Polymyxin B)|        |                     |                     |
| Blood 2008             | 80%      | 80%                 | 80%                 |
| Blood 2012             |          |                     |                     |
| p-value                |          |                     |                     |
|                       |          |                     |                     |
| **SXT** (Trimethoprim/sulfamethoxazole) |     |                     |                     |
| Blood 2008             | 54.70%   | 50%                 | 80%                 |
| Blood 2012             |          |                     |                     |
| p-value                | > 0.05   | > 0.05              |                     |
|                       |          |                     |                     |
| **TE** (Tetracycline)  |          |                     |                     |
| Blood 2008             | 60.50%   | 51%                 | 37.50%              |
| Blood 2012             |          |                     |                     |
| p-value                | > 0.05   | > 0.05              |                     |
|                       |          |                     |                     |
| **TOB** (Tobramycin)   |          |                     |                     |
| Blood 2008             | 76%      | 100%                | 100%                |
| Blood 2012             |          |                     |                     |
| p-value                | > 0.05   | > 0.05              |                     |
|                       |          |                     |                     |
| **TZP** (Piperacillin/Tazobactam) |   |                     |                     |
| Blood 2008             | 83.10%   | 90%                 | 100%                |
| Blood 2012             |          |                     |                     |
| p-value                | > 0.05   | > 0.05              |                     |

Values reported represent the proportion of isolates sensitive to the various antibiotics.

| PATIENTS | 2008 | 2012 | p-value | 2008 | 2012 | p-value | 2008 | 2012 | p-value |
|----------|------|------|---------|------|------|---------|------|------|---------|
| Blood    | 100% | 100% | 100%    | 100% |      |         |      |      |         |
| Urine    | 98.90%| 95%  | > 0.05  | 100% | 100% | > 0.05  | 100% | 100% | > 0.05  |
| Blood    | 61.40%| 73%  | > 0.05  | 66.70%|      |         |      |      |         |
| Urine    | 62.40%| 81%  | > 0.05  | 75%  |      |         |      |      |         |
| Blood    | 68.70%| 88%  | > 0.05  | 87.50%| 66.70%| > 0.05  | 90%  | 83.30%| > 0.05  |
| Urine    | 80%  | 80%  | > 0.05  | 80%  |      |         |      |      |         |
| Blood    | 54.70%| 50%  | > 0.05  | 37.50%| 64.30%| > 0.05  | 80.30%| 65.90%| < 0.05  |
| Urine    | 60.50%| 70%  | < 0.05  | 16.70%| 16.70%|         |      |      |         |
| Blood    | 76%  | 100% | 0%      | 89.30%|      |         |      |      |         |
| Urine    | 89.60%| 91%  | < 0.05  | 100%  |      |         |      |      |         |
| Blood    | 83.10%| 50%  | > 0.05  | 75%  |      |         |      |      |         |
| Urine    | 94.70%| 83%  | > 0.05  | 100%  | 100% | > 0.05  | 100% | 75%  | < 0.05  |
female in her 60s. Additional studies assessing other risk factors and virulence factors of the *E. coli* resulting in co-infection may be able to identify patients whose UTI should be treated more aggressively to prevent bacteremia. There may be little benefit in culturing the urine of a patient already being treated for an *E. coli* BSI as this study showed antibiotic susceptibility profiles will be identical 80% of the time. Based on the 2012 susceptibility profile, amikacin, piperacillin-tazobactam or a carbapenem are good choices for empiric treatment of suspected urosepsis. Tazobactam or a carbapenem are good choices for treatment of a UTI. Amoxicillin, trimethoprim, nitrofurantoin and lowest for the fluoroquinolones and resistance to this would be a good alternative as, contrary to what would be expected [10], resistance to this antibiotic decreased with time. The concern for antibiotic resistance weighs heavily in clinical practice and physicians may have a tendency to lean towards what is perceived as a more potent antibiotic. Similar to “older” antibiotics being reintroduced to treat multidrug resistant organisms [15], this “shelving”/decreased use of amoxicillin-clavulanate could explain its re-emergence as a contender in treating UTI in Jamaica. Ten antibiotics were noted in this study to have statistically significant reductions in susceptibility levels. It is clear that antibiotic resistance patterns can change drastically in a few years and a more rapid way of identifying the most current susceptibility antibiotic profile is needed locally. This further underscores the important role of antibiotic stewardship.

Because of the labor intensive restrictions in data collection in this study, the first six months of the respective years studied were arbitrarily chosen. Human errors are more likely to occur with data collection in this manner. In an attempt to counter this, the intradepartmental log was utilized. Though a 20% representation was obtained, missing data of over a month’s period may have affected results. Data was not available for all parameters studied as requisition forms sent by physicians for cultures were not always completely filled. Antibiotics may not have had susceptibility testing done on some *E. coli* isolates which may affect reported susceptibility percentages. Once *E. coli* was identified in urine, this study made the assumption that the patient had a UTI, colonization was not taken into account. Because of *E. coli*’s previously established role as a top pathogen in UTI and BSI, assumptions are made that its susceptibility profile can be used to identify empiric antibiotic choices; however this study did not specifically look at its current rank in causing infection locally and does not take into account differing susceptibility profiles of other top pathogens.

### Conclusion

The prevalence of *E. coli* infection in Jamaica matched that of other international studies. There is a female predominance with patients with BSI being older. Nitrofurantoin was identified as an appropriate choice for empiric therapy for UTI, but resistance patterns change drastically in 5 years making frequent antimicrobial susceptibility profiling necessary. Emerging antibiotic resistance was identified among ten antibiotics. This was the first study of its type in the Jamaican setting, to look specifically at *E. coli* UTI among patients with *E. coli* BSI in Jamaica which yielded a co-infection rate of 39%. Further studies on

| Antibiotic | 2008 | 2012 | p-value |
|------------|------|------|---------|
| AMP        | 28.90% | 42.10% | 0.05 |
| AMC        | 51.40% | 78.40% | < 0.05 |
| CAZ        | 95.50% | 78.90% | > 0.05 |
| CRO        | 81.40% | 73% | > 0.05 |
| CXM        | 73.80% | 50% | > 0.05 |
| CEFA       | 35% | 86.40% | < 0.05 |
| CEFE       | 63.60% | 85.70% | > 0.05 |
| CEF0       | - | 100% |
| TZP        | 81.80% | 93.80% | > 0.05 |
| ERT        | - | 100% |
| IMI        | 100% | 100% |
| MEM        | 100% | 100% |
| AZT        | - | 82.40% |
| SXT        | 40% | 51.10% | > 0.05 |
| NA         | 40.90% | - |
| F          | 100% | 84.80% | < 0.05 |
| Ak         | 100% | 93.90% | > 0.05 |
| CN         | 77.80% | 66.70% | > 0.05 |
| TOB        | 68.20% | 66.7%* | > 0.05 |
| TE         | - | 64.70% |
| MH         | 44.40% | - |
| CIP        | 55.90% | 51.50% | > 0.05 |
| LEV        | 45.50% | 60.90% | > 0.05 |
| NOR        | 50% | 42.90% | > 0.05 |

Values reported represent proportion of isolates sensitive to the various antibiotics. Antibiotic abbreviations used Ampicillin (AMP), Amoxicillin-clavulanate (AMC), Ceftriaxone (CRO), Cefuroxime (CXM), Cefzolin (CEF), Cephalosporin (CEFE), Cefotin (CEFO), Piperacillin/tazobactam (TZP), Ertapenem (ERT), Imipenem (IMI), Meropenem (MEM), Amoxicillin-clavulanate (AZT), Trimethoprim/sulfamethoxazole (SXT), Nitrofurantoin (F), Amikacin (AK), Gentamicin (CN), Tobramycin (TOB), Tetracycline (TE), Minocycline (MH), Ciprofloxacin (CIP), Levofloxacin (LEV), Norfloxacin (NOR).
this disease process would be beneficial in guiding management of these patients.

Acknowledgements
We would like to thank Professor John Lindo and the Research Group of the Department of Microbiology, UWI Jamaica, for their assistance and guidance in writing this manuscript.

References
1. Gordon KA, Jones RN (2003) Susceptibility patterns of orally administered antimicrobials among urinary tract infection pathogens from hospitalized patients in North America: comparison report to Europe and Latin America. Results from the SENTRY Antimicrobial Surveillance Program 2000. Diagn Microbiol Infect Dis 45: 295-301.
2. Manjunath GN, Prakash, R, Annam V, Shetty K (2011) Changing trends in the spectrum of antimicrobial drug resistance pattern of uropathogens isolated from hospitals and community patients with urinary tract infections in Tumkur and Bangalore. Int J Biomed Res 2: 504-507.
3. Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A (2009) The ARESC study: an international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int J Antimicrob Agents 34: 407-413.
4. Byam PR, Pierre RB, Christie CD, Andiman WA, Pettigrew M (2010) Antibiotic resistance among pathogens causing disease in Jamaican children with HIV/AIDS. West Indian Med J 59: 386-392.
5. Barton M, Bell Y, Thame M, Nicholson A, Trotman H (2008) Urinary tract infection in neonates with serious bacterial infections admitted to the University Hospital of the West Indies. West Indian Med J 57: 101-105.
6. Diekema DJ, Pfaller A, Jones RN, Doern GV, Winokur PL, Gales AC, Sader HS, Kugler K, Beach M, SENTRY Participants Group (Americas) (1999) Survey of bloodstream infections due to Gram-negative bacilli: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY antimicrobial surveillance program, 1997. Clin Infect Dis 29: 595-607.
7. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39: 309-317.
8. Bell Y, Barton M, Thame M, Nicholson A, Trotman H (2005) Neonatal sepsis in Jamaican neonates. Ann Trop Paediatr 25: 293-296.
9. Macfarlane DE, Narla VR (1985) Bacteraemia at the university hospital of the West Indies- a report of 222 cases. J Infect 10: 126-142.
10. McGregor JC, Elman MR, Bearden DT, Smith DH (2013) Sex- and age-specific trends in antibiotic resistance patterns of Escherichia coli urinary isolates from outpatients. BMC Fam Pract 14: 25.
11. Olesen B, Kolmos HJ, Orskov F, Orskov I, Gottschau A (1995) Bacteraemia due to Escherichia coli in a Danish University Hospital, 1986-1990. Scand J Infect Dis 27: 253-257.
12. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD (2008) Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect 14: 1041-1047.
13. Bo SN, Bo J, Ning YZ, Zhao Y, Lu XL, Yang JY, Zhu X, Yao GQ (2011) Relationship between time to positivity of blood culture with clinical characteristics and hospital mortality in patients with Escherichia coli bacteremia. Chin Med J 124: 330-334.
14. Jackson LA, Benson P, Neuzil KM, Grandjean M, Marion JL (2005) Burden of community-onset Escherichia coli bacteremia in seniors. J Infect Dis 191: 1523-1529.
15. Cassir N, Rolain JM, Brouqui P (2014) A new strategy to fight antimicrobial resistance: the revival of old antibiotics. Front Microbiol 5: 551.

Corresponding author
Dr. Alison Nicholson, MBBS, DM
Head of Department of Microbiology, University of the West Indies – Mona, Mona, Kingston 7, Jamaica, W.I.
Tel: 1(876)977-2206
Fax: 1(876)977-2289
Email: alison.nicholson@uwimona.edu.jm

Conflict of interests: No conflict of interests is declared.